Search

Displaying results 5531 - 5540 of 10000 in total
  1. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C.

  2. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  3. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  4. Drug

    Desidustat

    go.drugbank.com/drugs/DB16135
    Investigational

    Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

  5. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    Orca-T (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) is a donor-derived allogeneic cell therapy used in matched-donor hematopoietic stem cell transplantation for adults with blood … reconstitution and to improve chronic graft-versus-host disease-free survival, in adults with hematological malignancies.

  6. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    It provides patients with long term therapeutic benefit from a single administration rather than multiple injections. … Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.

  7. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  8. Drug

    Apoptone

    go.drugbank.com/drugs/DB06307
    Investigational

  9. Drug

    Eldelumab

    go.drugbank.com/drugs/DB06116
    Investigational

    MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory

  10. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to